Operator

Welcome to the Entrada Therapeutics Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Karla MacDonald, Chief Corporate Affairs Officer. Please go ahead.

Karla MacDonald
Chief Corporate Affairs Officer

Good morning, everyone, and thank you for joining us today. I'm Karla MacDonald, Chief Corporate Affairs Officer at Entrada Therapeutics. Today, we will be reviewing the positive top line results from Cohort 1 of participants living with Duchenne muscular dystrophy or DMD, treated with ENTR-601-44 in our Phase I/II ELEVATE-44-201 study.

Our news release, along with the accompanying slides can be found in the Investors section of our website.

Before we begin, I would like to note that we will be making some forward-looking statements during our presentation within the meaning of the U.S. Securities Act of 1934. These statements are based on Entrada's current beliefs and assumptions, are subject to risks and uncertainties and are not guarantees of future performance. Further, we undertake no obligations to revise or update any forward-looking statements.

We encourage you to review our SEC filings for more information.

Speaking on today's call are Dipal Doshi, our Chief Executive Officer; Dr. Natarajan Sethuraman, our President of Research and Development; and Dr. Laurent Servais, Professor